Developer Tools

New Pancreatic Cancer Pill Shrinks Tumors in Major Trial

New Pancreatic Cancer Pill Shrinks Tumors in Major Trial

⚡A pill that could double survival for one of the deadliest cancers.

Deep Dive

A new pill called daraxonrasib is being hailed as a major breakthrough for pancreatic cancer, one of the deadliest cancers. In a trial of 61 patients with advanced pancreatic cancer that had spread, the drug shrank tumors or made them disappear in over 60% of patients. In about 8% of patients, the cancer became undetectable on scans. After one year, 76.6% of patients were still alive, compared to 40-45% with chemotherapy alone. Doctors are calling this the closest to a cure they've seen for this disease.

Pancreatic cancer is particularly deadly: half of people diagnosed die within three months, and only about 3% survive five years once it spreads. The new drug works by targeting specific genetic mutations that drive tumor growth. These mutations are found in most pancreatic cancers and also in dozens of other cancers, raising hopes that the treatment could help many more people. The trial followed patients for an average of 18 months, and some have not seen the cancer return.

However, doctors caution that the pill is not yet a cure. They don't know how long it can keep the cancer at bay, and longer studies are needed. The results were presented at a medical conference and have not yet been published in a peer-reviewed journal. More trials are required before the treatment can be approved for widespread use. Still, for a cancer with such low survival rates, this offers real hope and could eventually lead to treatments for other cancers with similar mutations.

Key Points
  • In a trial, the pill daraxonrasib made cancer undetectable in 1 in 12 patients with advanced pancreatic cancer.
  • After one year, 76.6% of patients taking the pill were alive, compared to 40-45% with chemotherapy alone.
  • The drug targets mutations found in most pancreatic cancers and could potentially treat other cancers too.

Why It Matters

This could significantly extend lives for people with one of the deadliest cancers, offering hope where there was little.

🔒 FREE VIP ACCESS

Read the full breakdown & get daily AI executive intelligence

Join like-minded builders, researchers, and AI professionals who read The Neural Feed daily. 100% free. No spam.

🔔 BREAKING RELEASE RADAR INSTANT ALERTS • 1-CLICK PAUSE

Get instant breaking AI release alerts by topic

Choose the AI labs, models, or chip tracks you follow. Receive fast alerts only when something major ships — plus our free daily morning briefing.

Includes full article unlock • Only major releases • Unsubscribe anytime
🎁 FREE EXECUTIVE DOWNLOAD ISSUE #21

Download This Week's 8-Page Executive AI Briefing (PDF)

Our curated executive intelligence packet: in-depth breakdowns of frontier models, market movements, plus full-color AI comics.

  • ✓ 8-page formatted executive PDF briefing
  • ✓ Frontier AI models & technical breakthroughs
  • ✓ Full-color satirical AI comic strips
Instant 1-click download • 100% free • Unsubscribe anytime
📬 Get the top 10 AI stories daily